Interface Biologics Announces Series B Financing Round with DSM and BDC Capital

Toronto, ON, Canada, January 13, 2015 -- Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital. “Interface Biologics is a great strategic and a financial investment for DSM” remarked Pieter Wolters, Managing Director of DSM Venturing, the corporate venturing arm of Royal DSM, a €10 billion global science-based company active in health, nutrition and materials. “The fit with DSM’s activities in Biomedical offers significant opportunities to create incremental value.”

“BDC Capital has been an early and active investor in Interface Biologics since 2004” stated Dion Madsen, Senior Managing Partner in the Healthcare Venture Fund at BDC, “We believe the company is at the right stage to capitalize on the opportunity to work with a major strategic investor and accelerate the commercialization of its polymer technologies and the products that they enable.”

“We’re very pleased to have completed this Series B financing”, commented Tom Reeves, President & CEO of Interface Biologics. “Having a strategic investor like DSM in combination with BDC underscores both IBI’s success to date and the confidence that our investors have in our future. We look forward to working with DSM as we continue the commercial development of our surface modifying macromolecules and our drug delivery polymer technology platforms.”

Click here to view the full news release.